Inovio Pharmaceuticals Is Doing More Than Just Creating Buzz At BIO CEO 2017

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

When invited to host the BIO Buzz Center during the 2017 BIO CEO & Investor Conference in New York City on behalf of Life Science Leader magazine, I did not know who I’d be interviewing, just that I’d be doing about five video interviews with a number of industry executives and thought leaders. One of the people I had the opportunity to meet with was J. Joseph Kim, Ph.D., co-founder, president, and CEO of Inovio Pharmaceuticals (NASDAQ: INO). An entrepreneur, immunologist, and health policy leader, his biotechnology company is leading the world in developing novel immunotherapies (i.e., medicines that attack a broad array of cancers and challenging infectious diseases by training the body’s immune system to identify and fight disease). Prior to start his own company, Kim previously developed vaccines for Merck & Co. An immunologist by training, he has been recognized with numerous honors. In 2015, Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. Kim also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum (WEF) selected Dr. Kim as a member of its Global Agenda Council (2012) and named him a Technology Pioneer (2004) as well as one of its Young Global Leaders (2006). He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on Inovio’s breakthroughs and the pharmaceutical landscape. Below is my short video interview with Joseph Kim, Ph.D., co-founder, president, and CEO of Inovio Pharmaceuticals.